VAKCINA

Mór Thököly wrote:Preko 60%

This is an interim analysis based on 134 COVID cases among the 40,000 participants. The final analysis will be after another 80 cases, and "the overall vaccine efficacy may change," CureVac's CEO says. But not by much. https://t.co/xSCMZpOEDA

— Martin Enserink (@martinenserink) June 16, 2021

Here's my story about why I decided to drop out of the CureVac trial three weeks ago. (It had nothing to do with the vaccine's efficacy, which was unknown at the time.) https://t.co/aKf4kJVlKG

— Martin Enserink (@martinenserink) June 16, 2021

The trial in 10 countries in Latin America and Europe will continue, and a final result is expected in a few weeks. The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses, with the option to buy 180 million more.

“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” Franz-Werner Haas, CureVac’s chief executive, said in a statement.
...
Thirteen variants caused cases of covid-19 in the trial, with only a single case caused by the original SARS-CoV-2 virus. More than half of the cases were infections with variants of concern.

Out of 124 of the Covid-19 cases that the company’s scientists genetically sequenced, only one was caused by the original version of the coronavirus.

More than half of the cases were caused by variants that have been shown to be more transmissible or able to blunt the effectiveness of vaccines. CureVac’s volunteers were also infected by variants that have yet to be studied carefully. Lambda, which has come to dominate Peru in recent weeks, accounted for 21 percent of the samples.

As with the Moderna and BioNTech/Pfizer vaccines, CureVac’s jab uses mRNA but its mRNA is natural and unmodified. Its shot also uses a lower dose, 12 micrograms compared to Moderna’s 100mcg and BioNTech/Pfizer’s 30mcg, which results in a lower cost of production, and is stable at conventional fridge temperatures.

U FOKUSU

Kako je Kjurvek prokockao šansu veka

Dugo se mislilo da će prvi razviti vakcinu protiv korone, ali onda su ih drugi prestigli. Sada je pitanje da li će cepivo nemačkog Kjurveka uopšte dobiti dozvolu. Prve studije su poražavajuće.

Velika prašina digla se prošlog proleća kad se čulo da je Donald Tramp navodno ponudio milijardu evra da Kjurvek (Curevac), firma iz nemačkog Tibingena, pravi vakcine protiv korone samo za američko tržište. Ta nepristojna ponuda je odbijena, a Kjurvek je ostao najveća evropska nada, posebno kada se uortačio sa gigantom farmaceutske industrije Bajerom koji je trebalo da masovno proizvodi cepivo.

Nada je bila uzaludna, kako se ispostavilo. Ne samo da su nekoliki proizvođači napravili cepivo pre ove firme, već sada podaci kažu da Kjurvekova vakcina – koja je još u fazi ispitivanja – ima efikasnost od svega 47 odsto, nedovoljnu da dobije dozvolu. Kako je saopšteno, prvi presek pokazuje da delotvornost cepiva zavisi od starosti ljudi, kao i varijante korona-virusa.

U pitanju su tek međurezultati, ali vrednost akcija firme iz Tibingena na Vol stritu smesta je opala za polovinu.

Veliko razočaranje

Kjurvekovo cepivo, bazirano na mRNA tehnologiji kao i Bajontekovo i Modernino, nalazi se u poslednjoj fazi kliničkih ispitivanja sa 40.000 dobrovoljaca. U toj fazi, jedan deo njih dobija vakcinu, a drugi placebo, a onda se prati iz koje od te dve grupe se koliko ljudi zarazi koronom u svakodnevnom životu i kakav im je tok bolesti.

Prema saopštenju Kjurveka, do sada je otkriveno trinaest različitih varijanti korona-virusa među njihovim dobrovoljcima. Samo jedan jedini slučaj otpada na izvornu varijantu koja se proširila iz Kine, što govori da su mutacije potpuno preuzele primat.

Sada je izvesno da Kjurvekovo cepivo neće već u junu dobiti dozvolu Evropske agencije za lekove, a pitanje je da li će je dobiti uopšte. „Konačna efikasnost bi još mogla da bude drukčija“, rekao je generalni direktor firme Franc-Verner Has, priznajući da je očekivao bolje međurezultate.

Bolje rezultate je očekivao i nemački ministar zdravlja Jens Špan koji sada govori o „velikom razočaranju“.

EU htela 405 miliona doza

Nije ni čudo – Nemačka je već do kraja juna bila računala sa 1,4 miliona doza od Kjurveka. Evropska unija je unapred obezbedila ukupno 405 miliona doza ove vakcine koja, kako se čini, nikada neće ni krenuti u masovnu proizvodnju.

Menadžer magazin, koji se bavi temama iz poslovnog sveta, piše da je Kjurvek „prokockao šansu veka“. Prema viđenju tog magazina, milijarder i investitor Ditmar Hop poverio je stvar pogrešnom menadžmentu.

Drukčije se stvar odvijala u Majncu, gde je sedište Bajonteka koji je, u saradnji sa američkim Fajzerom, razvio prvu na zapadu odobrenu vakcinu protiv korone. Bajontekova vrednost je skočila u nebesa, a vodeći naučnik i osnivač firme Ugur Šahin došao je do bogatstva koje se procenjuje na 8,6 milijardi dolara.

Belgian court finds AstraZeneca "deliberately violated" contract with the EU by excluding British factory Oxford Biomedica in supplying contracted vaccines, and orders it to use the factory if needed to meet orders.
"AstraZeneca did not make its "Best Reasonable Efforts" it finds pic.twitter.com/lxdCBf3m7U

— Naomi O'Leary (@NaomiOhReally) June 18, 2021

Confusingly, both sides welcomed the judgment.
- AstraZeneca said it won, because the court says that the EU's order does not have priority over other contracts
- EU claimed victory as well, as the court found AZ violated its contract and that it should use the British factory

— Naomi O'Leary (@NaomiOhReally) June 18, 2021

Court says it can't order AZ to deliver all 220 mln doses because it can't pre-judge - the company may yet comply with its contract on those.
It also says it can't grant a "defacto priority right" to the EU, noting there are "contentious contractual obligations" to other buyers.

— Naomi O'Leary (@NaomiOhReally) June 18, 2021

The court's ruling on legal costs says "each of the parties is partially unsuccessful in their respective claims".
But it orders AstraZeneca to pay 70% of legal fees, and the European Union 30%. pic.twitter.com/vivQa9YeaK

— Naomi O'Leary (@NaomiOhReally) June 18, 2021

#BREAKING Palestinians scrap vaccine deal as Israel doses 'about to expire' pic.twitter.com/jr1TYcnyWi

— AFP News Agency (@AFP) June 18, 2021

Do danas je u Srbiji data 5.146.241 doza vakcine.

Ukupan broj građana koji su primili prvu dozu i onih koji su primili obe doze iznosi 2.693.998.

Obe doze primile su 2.452.243 osobe.

U Srbiji je prema najnovijim podacima dato ukupno 5.070.754 doza vakcina protiv korona virusa.

Ukupan broj građana koji su primili prvu ili obe doze je 2.681.511, dok je obe doze dobilo 2.389.243 ljudi.

Countries that performed the most COVID vaccinations in the last week:

Turkey 9.5% of the population
China 9.5%
Malta 8.8%
Canada 8.4%
Belgium 8.4%
Finland 7.6%
Uruguay 7.6%
Germany 6.7%
Dominican Republic 6.7%
Suriname 6.6%https://t.co/ErBxI1mDK2

— Edouard Mathieu (@redouad) June 21, 2021

Fascinating article focusing on the choices made surrounding the chemistry of the mRNA used in the Pfizer-BioNTech / Moderna vaccines versus the CureVac vaccine, and discusses if modified mRNA is the way to go in the future https://t.co/jQuqylJ4By

— Éimhear (A Little Haze Book Blog) (@alittlehaze) June 21, 2021